The FDA has approved Cipla's nintedanib capsules as a new generic version of Ofev for treating idiopathic pulmonary fibrosis ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and pirfenidone. The FIBRONEER trials support nerandomilast's efficacy in reducing ...

A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

United Therapeutics shares soared Monday on a "new era" for Tyvaso.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published full results of its phase 3 TETON-2 study ...

Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager. The offering is subject to market and ...

The FINANCIAL — Boehringer Ingelheim will present new data from its broad respiratory portfolio, which includes recently approved Spiolto Respimat (tiotropium ...

AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics (RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs ...

Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET Representatives: Trevi senior management will be joined by key opinion leaders in ...

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine The pivotal study of Tyvaso® (treprostinil) Inhalation ...